Treatment of estrogen deficiency symptoms in women surviving breast cancer- Part 4: Urogenital atrophy, vasomotor instability, sleep disorders, and related symptoms

There are several million breast cancer survivors worldwide. In the United States, 180, 000 women were diagnosed with breast cancel in 1997, and appro ximately 97,000 of these women have all extremely low chance of suffering a recurrence of their cancer. With an average age at diagnosis of 60 years a nd a 25-year expected duration of survival, the current number of breast ca ncer survivors in the United States may approach 2.5 million women. Since b reast cancer is now being detected at an earlier stage than previously and since adjuvant chemotherapy may cause ovarian failure, an increasing number of women are becoming postmenopausal at a younger age after breast cancer treatment. This conference was convened in September 1997 to consider how m enopausal breast cancer survivors should be treated at the present time and what future studies are needed to develop improved therapeutic strategies. A total of 47 breast cancer experts and 13 patient advocates participated, The proceedings of the conference are being published in six installments in successive issues of ONCOLOGY. This fourth part focuses on the treatment of urogenital atrophy, vasomotor instability, sleep disorders, and other r elated symptoms.